NCT04842747Phase 3Completed

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Study sponsor: Veru Inc. · VERU

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-07-06Actual
Enrollment · participants204Actual
Source updated2026-09-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.